DIA DIRECT: Drug Shortages and Supply Chain Management During COVID-19

Live Panel Discussion

August 5 | 9:00AM-10:00AM ET

Pharmaceutical supply chains have been under pressure during the COVID-19 pandemic, and our increasing dependence on offshore manufacturing of APIs and generics, as well as China and India's role as major suppliers, have come into renewed focus. Will the pandemic reshape supply chains and drug manufacturing? What drug and supply shortages have we experienced so far as a result of the pandemic? What steps can we take to minimize both current and future risks? Join us as a panel of experts tackle these questions as well as discuss a variety of topics, including:

  • Factors that put global medical supply chains at risk during a pandemic
  • Potential impact of the COVID-19 outbreak on global API production of generic and branded drugs and on the global pharma supply
  • Short- and long-term mitigation measures that could minimize risks and drive greater redundancy in the supply chain
  • Issues related to increased domestic manufacturing
  • Reliance on global supply chains in the development, manufacturing, and distribution of COVID-19 vaccines

Panelists:

  • Jeannie David, Senior Program Management Officer, CDER Drug Shortage Staff, OCD, FDA
  • Murray Lumpkin, DIA Fellow, Deputy Director, Integrated Development and Lead for Global Regulatory Systems Initiatives, Bill & Melinda Gates Foundation
  • Ping Zhang, Senior Director, Head of Industrial Affairs China, Sanofi